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Abstract: In recent years, there has been a growing interest in nutraceuticals, which may be considered
as an efficient, preventive, and therapeutic tool in facing different pathological conditions, including
thyroid diseases. Although iodine remains the major nutrient required for the functioning of the
thyroid gland, other dietary components play important roles in clinical thyroidology—these include
selenium, l-carnitine, myo-inositol, melatonin, and resveratrol—some of which have antioxidant
properties. The main concern regarding the appropriate and effective use of nutraceuticals in
prevention and treatment is due to the lack of clinical data supporting their efficacy. Another limitation
is the discrepancy between the concentration claimed by the label and the real concentration. This
paper provides a detailed critical review on the health benefits, beyond basic nutrition, of some popular
nutraceutical supplements, with a special focus on their effects on thyroid pathophysiology and aims
to distinguish between the truths and myths surrounding the clinical use of such nutraceuticals.
Keywords: nutraceuticals; thyroid function; dietary supplements
1. Introduction
1.1. Definition of Nutraceutical
The definition of nutraceuticals is still in the grey area between food, food supplements, and
pharmaceuticals. Some definitions [1–5] of nutraceuticals are provided in Table 1. The term
“nutraceutical” was coined in 1989 by Stephen De Felice, founder and chairman of the Foundation for
Innovation in Medicine, an American organization which encourages medical health research. He
defined a nutraceutical as a “food, or parts of a food, that provide medical or health benefits, including
the prevention and treatment of disease” [4]. Japan was among the first countries to face the issue
of regulating food supplements and foodstuffs. This legislation, originally set in 1991, evolved into
the 2003 Health Promotion Law [5]. The current European regulation (Regulation No. 1924/2006 of
the European Parliament and of the Council, recently updated by EU Regulation 2015/2283) defines
food categories and includes a definition of food supplements, although there is no official mention or
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recognition the term “nutraceutical” [6]. Accordingly, the European Food Safety Authority (EFSA)
does not make any distinction between “food supplements” and “nutraceuticals” for beneficial health
claim applications for new products. In a similar way, the Dietary Supplement Health and Education
Act (DSHEA, 1994) [7] defined dietary supplements as a category of food, as did the US Food and
Drug Administration (FDA) [8]. Indeed, in America “medical foods” and “dietary supplements” are
regulatory terms, however “nutraceuticals”, “functional foods”, and other such terms are determined by
consultants and marketers, based on consumer trends. Further information on the dietary supplements
given by the Food and Drug Administration (FDA) on its website [9] is summarized in Appendix
Table A1.
Table 1. Some definitions of “nutraceutical”.
Reference Definition
[1] “A foodstuff (such as a fortified food or dietary supplement) that provides health benefits inaddition to its basic nutritional value. (First known use: 1990)”.
[2] “A food to which vitamins, minerals, or drugs have been added to make it healthier.”
[3]
“Nutraceuticals, which have also been called medical foods, designer foods, phytochemicals,
functional foods and nutritional supplements, include such everyday products as “bio”
yoghurts and fortified breakfast cereals, as well as vitamins, herbal remedies and even
genetically modified foods and supplements. Many different terms and definitions are used in
different countries, which can result in confusion.”
[4]
“I propose to redefine functional foods and nutraceuticals. When food is being cooked or
prepared using “scientific intelligence” with or without knowledge of how or why it is being
used, the food is called ‘functional food’. Thus, functional food provides the body with the
required amount of vitamins, fats, proteins, carbohydrates, etc., needed for its healthy survival.
When functional food aids in the prevention and/or treatment of disease(s) and/or disorder(s)
other than anemia, it is called a nutraceutical.”
[5]
Nutraceutical combines two words the term ‘nutrition/nutrients’ (a nourishing food
component) and ‘pharmaceutical’ (medicine or a substance used as a medication) applied to
food or food component products sometimes with active principle from plants that can
provide health and medical benefits, including the prevention and treatment of disease.
1.2. Search of the Literature
A PubMed search, run on 14 July 2017, using the word “nutraceutical” as the entry, yielded
67,344 results. Results fell to 4820 using the entry “nutraceuticals AND hormones” and to 553 using
the entry “nutraceuticals AND thyroid”. Approximately 18 months later (5 February 2019), the
corresponding numbers were 78,919 (+17%), 5538 (+15%) and 642 (+16%), indicating that the interest
in the thyroid proceeds with the same pace as that for nutraceuticals in general and hormones in
general. Confirmation of these data came from a final search that was run on 9 July 2019 (Table 2).
In the following text, different nutraceuticals possibly influencing human thyroid function and/or
immunity will be reviewed and commented upon.
A general effect of the nutraceuticals beyond the thyroid effect is not within the scope of this
review, nor is a meticulous review of animal or other experimental studies. We were guided by
our clinical practices, particularly those for which patients were most curious. As mentioned in the
following section, there is indeed a growing market for such nutraceuticals.
There was relatively scant literature on the topic, and most research focused on thyroid cancer
and was experimental in nature, concerning the nutraceuticals illustratively mentioned by the Food
and Drug Administration, as shown in Appendix Table A1.
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Table 2. Summary of number of articles on given nutraceuticals retrievable on PubMed as of 9 July 2019.
Entry No. of Items Proportions
Total Human Human/Total Thyroid/Total Thyroid/Human
1 nutraceuticals 81,422 52,406 64.4% N/A N/A
2 nutraceuticals AND hormones 5698 3664 61.4% N/A N/A
3 nutraceuticals AND thyroid 656 487 74.2% 0.8% 0.9%
4 carnitine 16,737 7831 46.8% N/A N/A
5 carnitine AND thyroid 145 68 46.9% 0.9% 0.9%
6 inositol 44,801 16,700 37.3% N/A N/A
7 inositol AND thyroid 295 141 47.8% 0.6% 0.8%
8 melatonin 24,921 10,740 43.1% N/A N/A
9 melatonin AND thyroid 514 195 37.9% 2.1% 1.8%
10 resveratrol 11,983 5447 45.4% N/A N/A
11 resveratrol AND thyroid 78 47 60.2% 0.6% 0.9%
12 selenium 33,980 13,333 39.2% N/A N/A
13 selenium AND thyroid 938 576 61.4% 2.8% 4.3%
Note that the number of items under the keyword “nutraceuticals” underestimates the bulk of the literature. Indeed,
by adding items #4, 6, 10, 12, 14 and 16 the sum is 164,513, which is greater than 81,422 for item #1. Similar
considerations apply for the corresponding human studies (67,565 vs. 52,406), and for the thyroid studies (total
studies = 2305 vs. 656; human studies = 1269 vs. 487).
1.3. Market and Sales
Based on data from a decade ago, annual supplement sales were $23 billion, and about 40,000
supplement products were on the market in the United States [10]. In 2015, the American market for
dietary supplements was valued at $37 billion, with the economic impact in the United States for 2016
estimated at $122 billion, including employment wages and taxes [11]. One 2016 analysis estimated
the total market for dietary supplements could reach $278 billion worldwide by 2024 [11]. Table 3
summarizes the details for the nutraceuticals reviewed here [12–16].
Table 3. Economic issues for the reviewed nutraceuticals.
Nutraceutical Market and Sales ˆ
l-carnitine
l-carnitine market is expected to be worth USD 127 million by 2017, with the United States
being the largest market, and the Asia-Pacific region, particularly China, expected to
experience a 5.5% annual growth rate through 2017 [12].
No. of items on sale-Amazon: 53; Walgreens: No match; CVS Pharmacy:13.
Myo-inositol
In the consumption market, the global consumption value of inositol increases with the
2.01% average growth rate. Europe and China are the mainly consumption regions [11].
With myo-inositol being the most common form of inositols, over the next five years the
inositol market, will register a 6.8% compound annual growth rate in terms of revenue, the
global market size will reach US $140 million by 2024, from US $94 million in 2019 [13].
No. of items on sale-Amazon: 3; Walgreens: No match; CVS Pharmacy: No match.
Melatonin
The North America region is the largest supplier of melatonin, with a production market
share nearly 54% in 2016, Europe coming next with 27% [14]. The global market size will
reach US $2080 million by 2024, from US $700 million in 2019 [14].
No. of items on sale-Amazon: 122; Walgreens: 11; CVS Pharmacy: 91.
Resveratrol Resveratrol supplements, with annual sales of $30 million in the United States [15]No. of items on sale-Amazon: 45; Walgreens: No match; CVS Pharmacy: 19.
Selenium Selenium market reached $87 million U.S. in 2017 [16].No. of items on sale-Amazon: 91; Walgreens: No match; CVS Pharmacy: 84.
ˆ Numbers in brackets are references. Internet sales by Amazon, Walgreens and CVS Pharmacy are reported. Search
was performed for the pure nutraceutical, such as entering “pure melatonin”. Search performed on the Amazon
website by omitting the word “pure”, yielded a greater number of results (973 for l-carnitine, 48 for myo-inositol,
178 for resveratrol, over 1000 for selenium, and over 1000 for biotin). Search on the Walgreens website by omitting
the word “pure”, yielded a greater number of results (12 for l-carnitine, 1 for myo-inositol, 107 for melatonin, 10 for
resveratrol, 21 for selenium, and 71 for biotin).
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1.4. The Issue of Purity
“The biggest problem with supplements is that many of them do not actually contain what the
label claims. As many as 70% of the supplements on the market either don’t have ingredients that match
their labels or contain contaminants of some kind” [17]. In his review, Lockwood aimed to investigate
the extent of substandard formulated and raw material nutraceuticals [17]. The key findings were that
“published evaluations of over 70 formulations of 25 different nutraceuticals revealed variable quality;
no nutraceutical showed consistent high quality, but a number revealed consistent low quality, thereby
making the case for closer regulation of manufacturers. Whole food sources have also been shown
to be widely variable in constituent levels.” [17]. Concerning the issue of purity, the illegal presence
of thyroid hormones in the majority of dietary health supplements marketed for “thyroid support”
potentially exposes patients to the risk of developing iatrogenic thyrotoxicosis [18].
In the following text, we now give some data concerning the nutraceuticals dealt upon in our
paper. Concerning carnitine, of 12 over-the-counter carnitine formulations, the actual mean content
was only 52% of that indicated on the label [19]. Furthermore, of the same 12 preparations, five had
unsatisfactory pharmaceutical dissolution characteristics.
Concerning myo-inositol, one study evaluated label accuracy of four myo-inositol products,
designed for polycystic ovary syndrome (PCOS) treatment and available on the Italian market, and
performed a cost comparison based on myo-inositol content in milligrams for products analyzed [20].
A significant difference in the myo-inositol content, compared with the labeling was found for the
products. Only one product contained more than 95% of the myo-inositol content claimed on the label,
and there was a product with less than 75% of the labeling amount. Based on a 2-g myo-inositol per
day dose, the cost of a 30-day supply ranged from Euro 20.77 and Euro 71.86, after correction by the
actual amount of myo-inositol.
One recent study aimed to determine the dose of melatonin in food supplements marketed in
Europe (pharmacies of Spain) and the United States (supermarkets of San Francisco, CA, USA) by
validating a liquid chromatography method with diode array detection (LC-DAD) [21]. The authors
tentatively identified eight tryptophan-related contaminants in melatonin supplements, with only one
supplement declaring its addition on the label. Label melatonin doses varied from 1–1.95 mg/unit and
0.3–5 mg/unit for supplements marketed in Europe (Spain) and the US, respectively. Four out of 17
supplements showed significant deviations from melatonin content declared on the label (from −60%
to −20%). Only five out of the eight supplements purchased in Spain actually met the qualifications
needed to claim to reduce the time to fall asleep. Another study analyzed the actual melatonin content
(and presence of contaminants) in 31 melatonin supplements purchased from groceries and pharmacies
in one city in Canada [22]. Melatonin content varied from −83% to +478% of labeled melatonin and
approximately three-fourths had melatonin concentration ≤10% of what was claimed. Worse yet, the
content of melatonin between lots of the same product varied by as much as 465%. An additional 26%
of the 31 melatonin supplements were found to contain serotonin.
Concerning resveratrol, 14 brands of resveratrol-containing nutraceuticals were evaluated [23].
The 14 preparations were purchased directly from online stores during 2010 and were analysed
before their expiry dates. Only five out of 14 brands had near label values, compliant with Good
Manufacturing Practices (GMP) requirements (95%–105% content of active constituent), four products
were slightly out of this range (83%–111%) and three were in the 8%–64% range. Two samples were
below the limit of detection. The greater the difference between actual and labeled resveratrol content,
the lower the antioxidant and antiproliferative activity strength.
With regard to selenium, one study analysed six different brands of yeast-based selenium food
supplements that were obtained from local stores [24]. These supplements were treated with milder
extraction and hydrolysis conditions to analyse for the expected selenomethionine content. Only two
brands had high levels of selenomethionine, one brand appeared to contain all inorganic selenium,
and one brand appeared to contain greater than half inorganic selenium despite label claims of content
being only selenomethionine.
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2. Carnitine: Compound and Physiology
Carnitine is a quaternary ammonium compound (3-Hydroxy-4-(trimethylazaniumyl) butanoate)
that is ubiquitous in tissues and biological fluids of mammals [25]. The natural enantiomer is l-carnitine,
which acts as an obligatory cofactor for β-oxidation of fatty acids by facilitating the transport of the
long-chain fatty acids across the mitochondrial inner membrane as acyl-carnitine esters. This oxidation
liberates energy via the production of ATP in the respiratory chain, thus playing a role in cell’s energy
metabolism. Particularly, l-carnitine exerted a physiological benefit with a positive impact on cardiac
function through reduced oxidative stress, inflammation and necrosis of cardiac myocytes. [26]. Only
25% of the body stores of carnitine come from biosynthesis and 75% comes from the diet. The main
source is red meat and dairy products. Muscles are the most prominent carnitine depository since
they store about 95% of the 120 mmol total amount contained in the adult human body, and the
concentration in skeletal muscle (3.5 mmol/L) is 70-fold greater than that in plasma.
The main interest in carnitine supplementation comes from athletes and other physical exercise
performers [27]. Thus, repeated-dose carnitine supplements may increase skeletal muscle content.
For instance, long-distance runners given a daily dose of 2 g carnitine for 28 days and subjected to a
four-week training period [28] increased skeletal muscle carnitine by approximately 13% as compared
to a decrease of about 10% in placebo-treated athletes. In other athletes, supplementation with 1
g/day carnitine for 120 days of training increased carnitine concentrations in skeletal muscle by an
average of 9% compared to a decrease of 5% in the placebo-treated athletes [29]. Carnitine is critical
for normal skeletal muscle bioenergetics [30–32], and skeletal muscles suffer seriously in states of
carnitine deficiency. A relative carnitine deficiency can occur in athletes as a result of increased energy
metabolism, unbalanced nutrition, decreased skeletal muscle content and increased renal excretion of
carnitine. The important energetic role of carnitine, the relative deficiency associated with sustained
physical exercise, and the fact that carnitine is a natural compound, has led healthy subjects aiming
to improve their exercise performance to conclude that “more carnitine should be better [30–32], but
basically this was proven to be without any beneficial effect.
Carnitine and Thyroid Function
A German group of authors conducted pivotal clinical studies as early as 1959 in a very limited
number of patients with Graves’ disease, using a mixture of the two isomers (l-and d-carnitine) [33].
The first patient was a 53-year-old bedridden woman with very severe Graves’ disease and nervousness,
insomnia, weight loss, sweating, tachycardia and Graves’ orbitopathy. Basal metabolic rate (BMR)
was +82%, and she was administered 1 g/d d,l-carnitine. After 10 days, BMR was unchanged but one
week later it fell to +59%. Five weeks after starting d,l-carnitine, BMR was still +50% and the authors
switched to the naturally occurring l-carnitine. After only 10 days BMR dropped more rapidly to
+8% with associate improvement in general well-being and heart rate. Atrial fibrillation disappeared
and heart rate was 80–90 beats/min. To prove that the improvement was due to l-carnitine, it was
withdrawn in the 7th week from admission. BMR rose to +39%, but after rechallenge with l-carnitine
it fell again to +18% [33].
In the English-language literature, the first three monotherapy carnitine-treated hyperthyroid
patients were reported in the mid-1960s [34]. The authors found that patients became clinically
euthyroid without any consistent changes in the thyroid function tests, thus supporting the notion
that the antithyroid effect of carnitine is one of peripheral antagonism of thyroid hormone, rather
than a direct inhibition of thyroid gland function [35]. This was consistent with human tissue culture
experiments where l-carnitine inhibited both cell entry and, to a greater extent, nuclear entry of both T3
and T4 [36]. These data are consistent with carnitine being a peripheral antagonist of thyroid hormone
action, with a site of inhibition at or before the nuclear envelope [36].
The first controlled clinical trial addressing the value of l-carnitine in antagonizing elevated
circulating levels of thyroid hormones was conducted in 50 women under Thyroid stimulating
hormone (TSH)-suppressive l-T4 therapy for cytologically benign thyroid nodules who received
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a simultaneous treatment for six months with placebo (n = 10), or for given periods of time with
l-carnitine (2g/d or 4 g/d to test dose-dependence) [37]. Evaluation by both extensive clinical and
biochemical assessment demonstrated positive effects with the exception of osteocalcin, which increased
further during l-carnitine administration and partial exception of total cholesterol (minimal or no
increase during l-carnitine administration). Serum FT3, FT4 and TSH remained unchanged throughout
the 180 day-duration of the trial. Thus, there was no antagonism from l-carnitine on the negative
feedback that thyroid hormones exert on thyrotropin releasing hormone (TRH)/TSH. In addition to the
hypothalamic TRH-producing neurons and the pituitary thyrotropin, also osteoblasts were refractory
to the thyroid-hormone antagonizing effect of l-carnitine (see above). Thus, l-carnitine synergized with
thyroid hormone on the osteoblasts to increase osteocalcin serum concentrations. The favorable effect
on the osteoblasts was supported by measuring femur and lumbar bone density by dual-energy-X-ray
absorptiometry [37].
More recent cases of severe forms of Graves’ disease-related hyperthyroidism, including thyroid
storms, were treated successfully with l-carnitine [38–40]. Recently, a pilot study indicated the beneficial
effects of a combination of l-carnitine and selenium supplementation in subclinical hyperthyroidism [41].
A rationale for a beneficial effect of l-carnitine supplementation in hyperthyroid patients seems likely
because increased levels of thyroid hormones deprive the tissue deposits of l-carnitine itself [42], which
is further substantiated by the finding of decreased concentrations of carnitine in the skeletal muscles
of hyperthyroid patients. Interestingly, trendwise decreased concentrations of carnitine were found
in skeletal muscles of hypothyroid patients [43], which were restored upon regaining euthyroidism.
Therefore, decreased concentrations of carnitine in skeletal muscles may contribute to myopathy
associated with either hypothyroidism or hyperthyroidism.
Sixty thyroid-hormone adequately replaced hypothyroid Korean patients (age 50.0 ± 9.2 years,
57 females) continued to complain of fatigue [44]. These patients were given l-carnitine (990 mg
l-carnitine twice daily; n = 30) or placebo (n = 30) for 12 weeks. After 12 weeks, although neither
the fatigue severity score nor the physical fatigue score changed significantly after 12 weeks, but the
mental fatigue score was significantly improved by treatment with l-carnitine compared with placebo
(p < 0.01). In subgroups, both the physical and mental fatigue scores improved significantly in patients
younger than 50 years and those with free T3 ≥ 4.0 pg/mL by treatment with l-carnitine compared with
placebo. Other case-based studies have indicated a benefit from l-carnitine on hypothyroid symptoms,
but all of them have been case-based [45], while other studies may support benefits in the corticosteroid
hormone setting [46].
3. Inositol: Compound and Physiology
Inositol is a water-soluble compound closely associated with the vitamin B group (also known as
vitamin B8) [47]. Inositol is a carbohydrate which has a taste half as sweet as that of sucrose. Inositol
has long been known for its metabolic effects in humans, where it plays a part in the synthesis of
secondary messengers within cells. It is an essential component of the phospholipids that makes up
cellular membranes and is found in virtually all cells. The most abundant form of the nutrient is
myo-inositol. It assists in the transmission of nerve signals, helps to transport lipids within the body,
and is also critical for the proper action of insulin and maintenance of cellular calcium balance. Foods
containing the highest concentrations of myo-inositol include fruits, beans, grains and nuts. However,
in grains, it is in a non-available form called phytate. The more bioavailable form of inositol comes from
lecithin. Inositol is a necessary component of all cellular membranes. It is a member of the B-vitamin
family that contributes to muscular and nerve function and participates in the metabolism of fats in
the liver. Myo-inositol is the most abundant form of this nutrient, with its highest concentrations being
found in the brain and central nervous system. Myo-inositol in particular is a versatile nutrient for the
promotion of emotional and mental wellness, healthy eating patterns, and restful sleep through its
critical role in neurotransmitter messaging systems. In addition, it is an important nutritional element
for the maintenance of ovarian health and normal blood sugar maintenance, especially in women.
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Inositol is a non-essential member of the B-complex family with dietary sources from both animal
and plant foods. The form of inositol used in this product is myo-inositol, the most abundant form of
this nutrient. Inositol is found in all cell membranes, with the highest concentrations in the brain and
central nervous system, where it plays an important role in neurotransmitter signaling. Inositol is also
critical for the proper action of insulin, lipid metabolism, and for the maintenance of cellular calcium
balance. Inositol is a necessary component of all cellular membranes. It is a member of the inositols
are marketed as beneficial nutraceutics for improving mood and for the treatment of polycystic ovary
syndrome [20]. A significant difference in the myo-inositol content of available products, and there are
no regulations to ensure homogenous quality and accuracy [20].
Inositol and Thyroid Function/Autoimmunity
Inositols are essential for the signaling of hormones such as insulin, gonadotropins (follicle
stimulating hormone [FSH] and luteinizing hormone [LH]), and TSH. In the thyroid, imbalances in
the inositol metabolism can impair thyroidal hormone biosynthesis, storage and secretion [47]. TSH
signaling is rather complex involving two different signal cascades. One branch of the signal cascade
involves as second messenger cyclic AMP (cAMP), while another branch is inositol-dependent [48].
In a controlled trial, 48 women with autoimmune subclinical hypothyroidism were randomized to
treatment with either selenomethionine alone or selenomethionine plus myo-inositol. The authors
demonstrated that patients with autoimmune thyroiditis and subclinical hypothyroidism, treated with
myo-inositol and selenomethionine, had a reduction of the increased TSH, which selenomethionine
supplementation alone was not able to promote. However, the concentration of both thyroperoxidase
and thyroglobulin autoantibodies (TPOAb and TgAb) declined in both groups [48]. In a subsequent
study of 86 patients with Hashimoto’s thyroiditis and subclinical hypothyroidism, the same authors
found that the administration of myo-inositol and selenomethionine for six months significantly
decreased TSH, TPOAb, and TgAb concentrations, while at the same time enhancing thyroid hormones
and personal wellbeing, thereby restoring euthyroidism in patients diagnosed with autoimmune
thyroiditis [49]. This was confirmed in a larger study of 168 patients with Hashimoto’s thyroiditis and
subclinical hypothyroidism (TSH 3–6 mU/L) [50].
The mechanism of this effect might be through immune modulation rather than through thyroid
function per se [51]. Using the afore-mentioned combined treatment in 22 patients with autoimmune
thyroiditis, the initial TSH levels in the high normal range (2.1 < TSH < 4.0) significantly declined,
suggesting that the combined treatment can reduce the risk of progression to hypothyroidism in subjects
with autoimmune thyroid diseases. Antithyroid autoantibody levels also declined and, moreover,
the suspected immune-modulatory effect was confirmed by the finding that the concentration of the
chemokine CXCL10 also declined. Studies are, however, awaited to extend the observations in a
larger population, to evaluate the effect on the quality of life, and to study the mechanism of the effect
on chemokines.
Very recently, thyroid nodular disease also seemed to improve after the combined treatment with
myo-inositol and selenomethionine [52], but this also needs confirmation. Final data in this study
was analyzed from 34 patients with subclinical hypothyroidism: in 76% of mixed thyroid nodules a
significant reduction of their size was observed and 56% of them significantly regressed nodule stiffness
following oral supplementation with the combined nutraceutics for six months. The mean number of
mixed thyroid nodules shifted from 1.4 ± 0.2 to 1.1 ± 0.2 (p ≤ 0.05) and the TSH concentrations dropped
from 4.2 ± 0.2 mIU/L at baseline to 2.1 ± 0.2 mIU/L post-treatment (p < 0.001). In the control group,
38% of the thyroid nodules reduced their diameter but TSH concentrations significantly increased
up to the threshold after six months (from 4.0 ± 0.2 mIU/L to 4.3 ± 0.2 mIU/L, p ≤ 0.05). However,
further studies are required, both in vitro and in vivo, in order to investigate the mechanism of this
effect on the one hand, and a possible clinical treatment use of myo-inositol plus selenomethionine for
the general management of thyroid nodules on the other.
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4. Melatonin: Compound and Physiology
The isolation of melatonin was first reported in 1958 [53]. Since the demonstration that pineal
melatonin synthesis reflects both daily and seasonal time, melatonin has become a key element
of chronobiology research. In mammals, pineal melatonin is essential for transducing day-length
information into seasonal physiological responses. Due to its lipophilic nature, melatonin is able to
cross the placenta and is believed to regulate multiple aspects of perinatal physiology. The endogenous
daily melatonin rhythm is also likely to play a role in the maintenance of synchrony between circadian
clocks throughout the adult body. Pharmacological doses of melatonin are effective in resetting
circadian rhythms if taken at an appropriate time of day and can acutely regulate factors such as body
temperature and alertness, especially when taken during the day. Despite the extensive literature
on melatonin physiology, several key questions remain unanswered. Particularly the amplitude of
melatonin rhythms has recently been associated with diseases such as type 2 diabetes mellitus but the
physiological significance of melatonin rhythm amplitude remains poorly understood.
As a nutraceutical, melatonin is easily available over the counter and is marketed to regulate the
sleep pattern and adaptation to time zone differences among numerous other conditions.
Melatonin and Thyroid Function
Melatonin has antioxidant properties, which is one of the reasons why it is assumed to be beneficial
for many disease conditions. However, very few human studies exist, and they are primarily of
a physiological nature. One such study considers several endocrine and immune interactions in
healthy persons at different ages [54] and found statistically significant time-qualified correlations
among lymphocyte subset percentages and hormone serum levels in the young and middle aged
and one could speculate that the phenomenon of lymphocyte subpopulation redistribution may be
more complex, and may involve other hormones such as TRH, TSH, GH (growth hormone), IGF1
(insulin-like growth factor 1), monoamines such as melatonin, cytokines such as IL2 (Interleukin 2),
and chemokines. The aging of immune system function may be related to the alteration of circadian
rhythmicity, with a loss of interaction among key lymphocyte subsets, immunomodulating hormones,
as well as cytokines/chemokines.
Thirty-six perimenopausal and 18 postmenopausal women between 42 and 62 years of age with
no pathology or medication were selected for a randomized study of melatonin or placebo at bedtime
(22:00–00:00). The melatonin concentration was measured in saliva to divide the participants into
low, medium, and high-melatonin subjects [55]. Three- and six-months later, blood was taken for the
determination of pituitary (LH and FSH), ovarian, and thyroid hormones (T3 and T4). The results
showed that women low in melatonin after treatment with melatonin significantly increased thyroid
hormones levels and improved gonadal functions [55]. These results were confirmed by the same
authors in another study where peri- and menopausal women (N = 139) took a daily dose of 3 mg
synthetic melatonin or placebo for 6 months. Melatonin concentrations were determined from five daily
saliva samples at fixed times while other hormone levels were determined from blood samples three
times over the six-month period [56]. The conclusion was that the six-months treatment with melatonin
produced a remarkable and highly significant improvement of thyroid function, positive changes of
gonadotropins towards more juvenile levels, and the abrogation of menopause-related depression.
In 40 menopausal women the combination of myo-inositol plus melatonin seemed to positively
affect glucose metabolism. Myo-inositol alone seemed to improve thyroid function, while addition
of melatonin increased the serum TSH concentration [57]. The reason for this is unknown, but all
melatonin products warn against worsening of autoimmune diseases on basis of its potential effect on
the immune system. Recently, SNPs related to melatonin receptor gene polymorphism haplotypes were
associated with susceptibility to Graves’ disease in an ethnic Chinese population and thus support the
involvement of the melatonin pathway in the pathogenesis of this autoimmune thyroid disease [58].
In conclusion, there is to date no controlled trials to substantiate a use of melatonin for general
thyroid health improvement.
Nutrients 2019, 11, 2214 9 of 19
5. Resveratrol: Compound and Physiology
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) belongs to the flavonoids family and is a major
natural polyphenolic compound found in several fruit and vegetables such as grapes, peanuts, and
peanut sprouts. It seems to play an important role as a therapeutic and chemopreventive agent used
in the treatment of various illnesses [59,60] and has therefore recently gained much attention among
health professionals as well as other nutrition experts. Resveratrol exhibits effects against several
cancers [61,62] through different pathways and, furthermore, it has antidiabetic, anti-inflammatory, and
antioxidant effects. The cardiovascular protective capacities of resveratrol are believed to be associated
with multiple molecular targets such as inflammation, oxidative stress, apoptosis, mitochondrial
dysfunction, angiogenesis and platelet aggregation [59].
Similarly, resveratrol is a potent scavenger for free radicals. The high efficiency of resveratrol might
be due to the three hydroxyl groups in its structure. Thus, the use of resveratrol as a health-promoting
dietary supplement is rapidly increasing in today’s market. Many reports have shown that resveratrol
offers a wide range of preventive and therapeutic alternatives against various diseases including
different types of cancer.
Resveratrol is a member of a family of enzymes, under the general name of stilbene synthase,
which makes up part of a larger family of proteins with numerous functions. Notably, its chemical
structure resembles that of l-T4, however it is not clear if this has any functional implications [63].
Resveratrol synthase is developed from chalcone synthase via gene duplication and mutations. The
absorption in humans is approximately 75% (delayed by food) by trans-epithelial diffusion, while
tissue accumulation enhances efficacy at target sites.
Resveratrol and Thyroid Function
Resveratrol may arrest the proliferation of thyroid cancer cells by increasing the abundance and
phosphorylation of p53 [64–66]. Moreover, resveratrol mediates the regulation of TSH while, due
to its effects on iodine trapping, it shows promise as a prospective anti-thyroid drug. On the other
hand, these effects also resulted in a pronounced proliferative action on thyrocytes and resveratrol
may therefore be a thyroid disrupting compound [67]. No clinical studies on the compound’s effect on
the thyroid has been performed in humans, so all available evidence is based on animal and in vitro
cellular studies.
Finally, resveratrol as an antioxidant agent is a free radical scavenger and this property can
be of interest in thyroid disease states that are accompanied by increased production of hydrogen
peroxide and radical oxygen species, such as autoimmune thyroiditis and hyperthyroidism [68]. Proper
randomized clinical trials would, however, be required before implementing any use.
Resveratrol supplements can be easily purchased over the counter but they are not regulated
by the FDA or any other health authority. Most resveratrol capsules sold in the U.S. contain extracts
from an Asian plant called Polygonum cuspidatum. Other resveratrol supplements are made from red
wine or red grape extracts. The dosages in most resveratrol supplements typically contain 250 to
500 milligrams, which is much lower than the amounts that have been shown beneficial in research
(2000 milligrams of resveratrol or more a day).
6. Selenium: Compound and Physiology
Selenium is a non-metal chemical element that is an essential micronutrient. Selenium salts are
toxic in large amounts, but trace amounts are necessary for cellular function in many organisms,
including all animals. Dietary selenium comes from nuts, cereals, and mushrooms. Brazil nuts are the
richest dietary source (though this is soil-dependent since the Brazil nut does not require high levels of
the element for its own needs). Selenium is an ingredient in many multivitamins and other dietary
supplements. It is a component of the antioxidant enzymes glutathione peroxidase and thioredoxin
reductase, which indirectly reduce certain oxidized molecules in animals and some plants. It is also
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found in three deiodinase enzymes, which convert one thyroid hormone to another. In living systems,
selenium is found in the amino acids selenomethionine, selenocysteine, and methylselenocysteine.
The U.S. recommended dietary allowance (RDA) for teenagers and adults is 55 µg/day. Selenium
as a dietary supplement is available in many forms, including multi-vitamins/mineral supplements,
which typically contain 55 or 70 µg/serving. Selenium-specific supplements typically contain either
100 or 200 µg/serving. In June 2015, the U.S. FDA published its final rule establishing the requirement
of minimum and maximum levels of selenium in infant formula. The reference values of EFSA for
selenium range from 15 µg/day for children aged one to three years to 70 µg/day for adolescents
aged 15–17 years [69]. The selenium content in the human body is believed to be in the range of
13–20 milligram [70].
Selenium food supplements are most efficient as yeast-based selenomethionine, but the contents
are not standardized or under any control. For instance, six different brands of yeast-based selenium
food supplements were analysed for the expected selenomethionine content [23]. Only two brands
had high levels of selenomethionine; one brand appeared to contain only inorganic selenium, and
one brand appeared to contain more than half inorganic selenium despite label claims of content
being only selenomethionine. Nevertheless, selenium supplementation is increasingly prescribed by
endocrinologists as recently documented for Italian endocrinologists [70]. In detail, approximately
one in four respondents use selenium often/always, with only one in either use never. Rates were
approximately one-fourth of respondents prescribing selenium often/always in Hashimoto’s thyroiditis,
and one-fifth prescribing selenium in the case presented. In patients with autoimmune thyroiditis
(AIT) who are planning pregnancy or are already pregnant, approximately 40% of respondents
suggest selenium use [71]. It is worth underlining that the American Thyroid Association (ATA)
pregnancy guideline reported that “selenium supplementation is not recommended for the treatment
of TPOAb-positive women during pregnancy” [72].
Selenium and Thyroid Function/Autoimmunity
Among all tissues, the thyroid gland has the highest concentration of selenium, of which much is
stored in the thyrocytes as the selenoproteins [73,74]: deiodinases (DI1, DI2), glutathion peroxidase
(GPx1, GPx3, GPx4), and thioredoxin reductases (TR1, TR2). Both the thyroid gland and all other cells
that are dependent of thyroid hormone for proper function use selenium as a cofactor for three of the
four known types of thyroid hormone deiodinases, which can both activate and deactivate thyroid
hormones and their metabolites—the iodothyronine deiodinases are the subfamily of deiodinase
enzymes that use selenium, as does the otherwise rare amino acid selenocysteine. Only iodotyrosine
deiodinase does not use selenium.
Adequate selenium intake is required for normal function of thyrocytes and the angiofollicular
units in thyroid hormone biosynthesis and storage. Inadequate selenium intake has been associated
with increased thyroid volume in females, but not males in one study [75], and in a larger Danish
population, this negative correlation between selenium status and thyroid volume was confirmed,
and there was, furthermore, a trend toward increased numbers of thyroid nodules with inadequate
selenium status [74,76]. Adequate selenium intake, with respect to proper thyroid function, can be
monitored by the analysis of serum or plasma selenoproteins such as selenoprotein P or plasma
GPx3 [74,77,78]. Intoxication has been reported in several places in China from dietary intake and
soil contamination [79,80]. Measurement of these variables is becoming more important in the view
of the increased interest in selenium supplementation in various patient groups particularly with
autoimmune thyroid diseases (see below) and since there is a risk of overdosing by general too high
doses on the one hand and supplementation of selenium sufficient individuals on the other. The
U-shaped curve of beneficial effects from selenium concentrations, i.e., exhibiting major advantages
in selenium-deficient individuals but specific health risks in those with selenium excess should be
seriously considered [81].
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Selenium status has been shown to affect immune functions, e.g., T cell differentiation, and
selenium deficiency has been associated with Th2 cells/markers, while higher selenium concentrations
seem to favor an increased Th1 and Treg response [82]. These observations are thus in keeping
with the suggestion of beneficial effects of selenium supplementation in autoimmune diseases of the
thyroid [73,83]. Newly diagnosed autoimmune hyperthyroidism, Graves’ disease, has been associated
with low selenium concentrations [84], an observation which has fuelled several interventional treatment
studies of selenium supplementation as adjunctive to antithyroid drugs in Graves’ disease [85–88].
A very recent systematic review and meta-analysis of 10 randomized clinical trials could not substantiate
a systematic effect of selenium supplementation as an adjunctive treatment in Graves’ disease [89].
Generally, the studies were all underpowered, of too short a duration, and with too broad clinical
characteristics of the patients, and the issue is therefore yet to be resolved—results from larger ongoing
prospective studies are awaited [90].
Concerning the subpopulations of Graves’ disease, however, a prospective case-control study
demonstrated lower serum selenium concentrations in patients with Graves’ orbitopathy compared
to Graves’ patients without orbitopathy in an Australian study population with marginal selenium
status [91]. Against this background, relative selenium deficiency may be an independent risk factor
for orbitopathy in patients with Graves’ diseases. This has been further substantiated by one major
multicentric prospective, placebo and serum-controlled study of Graves’ patients with orbitopathy,
with demonstration of improved quality of life and disease activity scores [92].
Several placebo-controlled and double-blind studies, both observational and prospective,
have been performed to demonstrate the improved quality of life, wellbeing, thyroid hormone
status, and disease symptoms of chronic autoimmune thyroiditis of the Hashimoto type with or
without hypothyroidism. Although many studies have consistently demonstrated a reduction in
thyroid autoantibody concentrations by selenium supplementation, including some compared with
control/placebo [93–96], recent meta-analyses found insufficient evidence for the clinical efficacy
of selenium supplementation in chronic autoimmune thyroiditis [97,98]. Hopefully, future trials
can ultimately provide reliable evidence to help inform clinical decision making. Results were less
optimistic than the individual study results, many of which were, however, underpowered, and
therefore, in this autoimmune patient group, results are unclear and further ongoing study results are
awaited [99].
In women at risk of postpartum thyroiditis, adequate selenium status prevents its development.
In a prospective placebo-controlled double-blind prevention study [100], there were fewer cases of
postpartum thyroiditis—these results, however, have not been confirmed in other studies [73,101].
Finally, there has been no indication of an increased risk of thyroid cancer in either selenium
deficiency or with supplementation of selenium [74].
In conclusion, selenium status has a high impact on normal thyroid development and function,
and it is still a potential candidate for improvement of clinical markers and quality of life in some
situations of autoimmune thyroid diseases by supplementation, e.g., Graves’ orbitopathy and possibly
postpartum thyroiditis. However, more solid evidence is awaited until firm conclusions can be made
concerning recommendations for global routine clinical use.
7. Perspective and Conclusions
As clinicians, we often see patients who are taking all sorts of supplements with the hope of
improving their health and medical conditions, as well as simply feeling better.
Thyroid supplements attract a disproportionately large amount of attention, just as the thyroid
gland gets “blamed” for multiple symptoms. There are truths and myths that this review had tried to
clarify. Of the numerous nutraceuticals out there for thyroid disease management, we focused on the
common or popular ones we encounter in the clinical practice.
Clinicians should acknowledge that over 30% of our patients are using supplements and thus
should inquire about them during our office encounters. Apart from improving their general health,
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patients are using these alleged thyroid supplements to help “improve their metabolism, have more
energy, and to lose weight”.
It is important that we do not just dismiss these patients, but rather have honest discussions about
the claimed benefits and potential risks. Physicians would do well to familiarize themselves with the
main supplements being used, and also to know the scientific evidence available to support or refute
these claims. More importantly, physicians should understand the potential risks or side effects in
order to properly counsel patients about their use.
Based on the literature reviewed in the preceding sections, the evidence for the clinical use
and potential benefit of the nutraceuticals addressed in this paper is summarized in Table 4. It is,
however, worth noting that very few studies have been randomized clinical trials and generally all the
studies have lacked proper power and even attempts to perform power calculations including the
few randomized clinical trials. For selenium, two randomized, properly powered, placebo controlled
clinical trials are ongoing and results are awaited [89,98]. Similar studies are required also for the most
relevant nutraceuticals with a possible influence on the thyroid, in order to provide proper guidance
both to patients and clinicians.
Table 4. Summary of evidence for clinical use of the nutraceuticals reviewed here in the thyroid setting *.
Question: Is There
Evidence for
Clinical Use of . . . ?
Answer
Carnitine
Currently available evidence supports the usefulness of l-carnitine in hyperthyroid
patients. Carnitine ameliorates a number of symptoms and signs, including cardiac
arrhythmia. Case reports have shown benefits even in the setting of thyroid storm.
However, no changes in thyroid function tests were reported.
One practical setting for the use of l-carnitine (two grams per day) is the control of
hyperthyroidism symptomatology when the patients need to take low doses of
antithyroid drugs. Only one Korean study is currently available for hypothyroidism,
thus precluding conclusions.
Inositols
Only in one study, MI alone (2 g twice a day) or MI plus melatonin (2 g/d MI plus 3 g/d
melatonin) were given in two groups of euthyroid postmenopausal women, and serum
FT4 and TSH evaluated. MI alone caused an almost 3.5% increase in serum FT4 and a
10% decrease in serum TSH. This contrasted with the opposite changes (3.5% decrease
in serum FT4 and almost 10% increase in serum TSH) observed in the group under MI
plus melatonin.
Few studies have been conducted only in one Western country (Italy), and with the
combination of MI plus selenium or MI plus carnitine. Supplementation with the first
combination has been used in the setting of patients with Hashimoto’s thyroiditis
related SCHypo, and it decreased both serum thyroid autoantibodies and TSH. The
combination of MI plus carnitine was only investigated in one study of patients with
SCHyper, thus precluding conclusions.
Melatonin
There has been interest in melatonin and autoimmunity and the thyroid gland has been
implicated in the discussion. It is thought that melatonin may have a paracrine role
and in thyroid disease under a condition of oxidative stress may reduce the processes
involved in thyroid antoimmunity. However, there are no controlled trials or definite
data to show conclusively that melatonin can be beneficial in thyroid disease.
Resveratrol No answer can be given, simply for lack of studies.
Selenium
Benefits have been demonstrated for mild forms of Graves’ ophthalmopathy. Benefits
for the clinical course of GD itself are controversial. In the setting of HT, a benefit has
been shown more on serum thyroid autoantibodies than on thyroid function. There is
only one study on the benefit given by selenium supplementation, both in terms of
serum thyroid autoantibodies and thyroid dysfunction, in the setting of PPT. For the
combinations of selenium with MI see above.
Abbreviations, in alphabetical order: GD = Graves’ disease; HT = Hashimotos’ thyroiditis; MI = myo-inositol;
PPT = postpartum thyroiditis. SCHyper = subclinical hyperthyroidism; SCHypo = subclinical hypothyroidism.
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Appendix A
Table A1. Information on the dietary supplements provided by the Food and Drug Administration *.
Questions Answers
What is a dietary
supplement? §
Congress defined the term “dietary supplement” in the Dietary Supplement Health and
Education Act (DSHEA) of 1994. A dietary supplement is a product taken by mouth that
contains a “dietary ingredient” intended to supplement the diet. The “dietary ingredients”
in these products may include vitamins, minerals, herbs or other botanicals, amino acids,
and substances such as enzymes, organ tissues, glandulars, and metabolites. Dietary
supplements can also be extracts or concentrates and may be found in many forms such as
tablets, capsules, softgels, gelcaps, liquids, or powders. They can also be in other forms,
such as a bar, but if they are, information on their label must not represent the product as a
conventional food or a sole item of a meal or diet. Whatever their form may be, DSHEA
places dietary supplements in a special category under the general umbrella of “foods”,
not drugs, and requires that every supplement be labeled a dietary supplement.
What is a “new dietary
ingredient” in a dietary
supplement? §
The Dietary Supplement Health and Education Act (DSHEA) of 1994 defined both of the
terms “dietary ingredient” and “new dietary ingredient” as components of dietary
supplements. In order for an ingredient of a dietary supplement to be a "dietary
ingredient," it must be one or any combination of the following substances:
a vitamin,
a mineral,
an herb or other botanical,
an amino acid,
a dietary substance for use by man to supplement the diet by increasing the total dietary
intake (e.g., enzymes or tissues from organs or glands), or a concentrate, metabolite,
constituent or extract.
A “new dietary ingredient” is one that meets the above definition for a “dietary ingredient”
and was not sold in the U.S. in a dietary supplement before 15 October 1994.
What are the benefits of
dietary supplements?
Some supplements can help assure that you get enough of the vital substances the body
needs to function; others may help reduce the risk of disease. But supplements should not
replace complete meals which are necessary for a healthful diet–so, be sure you eat a
variety of foods as well.
Unlike drugs, supplements are not permitted to be marketed for the purpose of treating,
diagnosing, preventing, or curing diseases. That means supplements should not make
disease claims, such as “lowers high cholesterol” or “treats heart disease.” Claims like
these cannot be legitimately made for dietary supplements.
Are there any risks in
taking supplements?
Yes. Many supplements contain active ingredients that have strong biological effects in the
body. This could make them unsafe in some situations and hurt or complicate your health.
For example, the following actions could lead to harmful–even
life-threatening–consequences.
Combining supplements
Using supplements with medicines (whether prescription or over the counter)
Substituting supplements for prescription medicines
Taking too much of some supplements, such as vitamin A, vitamin D, or iron
Some supplements can also have unwanted effects before, during, and after surgery. So, be
sure to inform your healthcare provider, including your pharmacist about any
supplements you are taking.
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Table A1. Cont.
Questions Answers
Some Common Dietary
Supplements
Calcium
Echinacea
Fish Oil
Glucosamine and/or
Chondroitin Sulphate
Garlic
Vitamin D
St. John’s Wort
Saw Palmetto
Ginkgo
Green Tea
Note: These examples do not represent either an endorsement or approval by FDA.
How can I find out
more about the dietary
supplement I’m taking?
Dietary supplement labels must include name and location information for the
manufacturer or distributor.
If you want to know more about the product that you are taking, check with the
manufacturer or distributor about:
Information to support the claims of the product.
Information on the safety and effectiveness of the ingredients in the product.
Report Problems to
FDA
Notify the FDA if the use of a dietary supplement caused you or a family member to have
a serious reaction or illness (even if you are not certain that the product was the cause, or
you did not visit a doctor or clinic).
Follow these steps:
• Stop using the product.
• Contact your healthcare provider to find out how to take care of the problem.
• Report problems to FDA in either of these ways:
• Contact the Consumer Complaint Coordinator in your area.
• File a safety report online through the Safety Reporting Portal.
§ Source is [7]. * Source is [8].
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